Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small-Cell Lung Cancer
media
posted on 2021-05-26, 16:20 authored by Adis journals on behalf of, Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan<div><b>Article full text</b></div><div><br></div><div>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). </div><div>© The authors, CC-BY-NC 2021. </div>
